Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J.

Ann Oncol. 2018 Apr 1;29(4):1076. doi: 10.1093/annonc/mdx776. No abstract available.

PMID:
29253076
2.

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J.

Ann Oncol. 2016 Nov;27(11):2032-2038. Epub 2016 Aug 29. Erratum in: Ann Oncol. 2018 Apr 1;29(4):1076.

3.

Regulation of Thrombin-Induced Lung Endothelial Cell Barrier Disruption by Protein Kinase C Delta.

Xie L, Chiang ET, Wu X, Kelly GT, Kanteti P, Singleton PA, Camp SM, Zhou T, Dudek SM, Natarajan V, Wang T, Black SM, Garcia JG, Jacobson JR.

PLoS One. 2016 Jul 21;11(7):e0158865. doi: 10.1371/journal.pone.0158865. eCollection 2016.

4.

Extracellular Vesicles from Caveolin-Enriched Microdomains Regulate Hyaluronan-Mediated Sustained Vascular Integrity.

Mirzapoiazova T, Lennon FE, Mambetsariev B, Allen M, Riehm J, Poroyko VA, Singleton PA.

Int J Cell Biol. 2015;2015:481493. doi: 10.1155/2015/481493. Epub 2015 Sep 10.

5.

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.

Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, Singleton PA.

Front Oncol. 2015 Jul 21;5:164. doi: 10.3389/fonc.2015.00164. eCollection 2015.

6.

The mu opioid receptor: A new target for cancer therapy?

Singleton PA, Moss J, Karp DD, Atkins JT, Janku F.

Cancer. 2015 Aug 15;121(16):2681-8. doi: 10.1002/cncr.29460. Epub 2015 Jun 4. Review.

7.

Hyaluronan regulation of endothelial barrier function in cancer.

Singleton PA.

Adv Cancer Res. 2014;123:191-209. doi: 10.1016/B978-0-12-800092-2.00007-1. Review.

8.

Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.

Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA.

J Biol Chem. 2014 Aug 29;289(35):24043-58. doi: 10.1074/jbc.M114.554766. Epub 2014 Jul 14.

9.

Increased μ-opioid receptor expression in metastatic lung cancer.

Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J.

Br J Anaesth. 2014 Jul;113 Suppl 1:i103-8. doi: 10.1093/bja/aeu165. Epub 2014 Jun 11.

10.

GRP78 is a novel receptor initiating a vascular barrier protective response to oxidized phospholipids.

Birukova AA, Singleton PA, Gawlak G, Tian X, Mirzapoiazova T, Mambetsariev B, Dubrovskyi O, Oskolkova OV, Bochkov VN, Birukov KG.

Mol Biol Cell. 2014 Jul 1;25(13):2006-16. doi: 10.1091/mbc.E13-12-0743. Epub 2014 May 14.

11.

The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA.

PLoS One. 2014 Mar 24;9(3):e91577. doi: 10.1371/journal.pone.0091577. eCollection 2014.

12.

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.

Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R.

Cancer Biol Ther. 2013 Jul;14(7):679-91. doi: 10.4161/cbt.25091. Epub 2013 May 31.

13.

Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity.

Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR.

J Biol Chem. 2013 Jan 25;288(4):2191-200. doi: 10.1074/jbc.M112.404780. Epub 2012 Dec 4.

14.

Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury.

Sun X, Singleton PA, Letsiou E, Zhao J, Belvitch P, Sammani S, Chiang ET, Moreno-Vinasco L, Wade MS, Zhou T, Liu B, Parastatidis I, Thomson L, Ischiropoulos H, Natarajan V, Jacobson JR, Machado RF, Dudek SM, Garcia JG.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):628-36. doi: 10.1165/rcmb.2012-0048OC. Epub 2012 Jul 5.

15.

The μ-opioid receptor in cancer progression: is there a direct effect?

Lennon FE, Moss J, Singleton PA.

Anesthesiology. 2012 Apr;116(4):940-5. doi: 10.1097/ALN.0b013e31824b9512. Review. No abstract available.

PMID:
22357347
16.

Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA.

Anesthesiology. 2012 Apr;116(4):857-67. doi: 10.1097/ALN.0b013e31824babe2.

PMID:
22343475
17.

Hyaluronan regulation of vascular integrity.

Lennon FE, Singleton PA.

Am J Cardiovasc Dis. 2011;1(3):200-13. Epub 2011 Sep 10.

18.

Novel role for non-muscle myosin light chain kinase (MLCK) in hyperoxia-induced recruitment of cytoskeletal proteins, NADPH oxidase activation, and reactive oxygen species generation in lung endothelium.

Usatyuk PV, Singleton PA, Pendyala S, Kalari SK, He D, Gorshkova IA, Camp SM, Moitra J, Dudek SM, Garcia JG, Natarajan V.

J Biol Chem. 2012 Mar 16;287(12):9360-75. doi: 10.1074/jbc.M111.294546. Epub 2012 Jan 4.

19.

Acute Lung Injury Regulation by Hyaluronan.

Singleton PA, Lennon FE.

J Allergy Ther. 2011 Dec 20;Suppl 4. doi: 10.4172/2155-6121.S4-003.

20.

Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology.

Lennon FE, Singleton PA.

Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L137-47. doi: 10.1152/ajplung.00071.2010. Epub 2011 May 13. Review.

21.

The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.

Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA.

Anesth Analg. 2011 Mar;112(3):558-67. doi: 10.1213/ANE.0b013e31820568af. Epub 2010 Dec 14.

22.

Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function.

Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, Singleton PA, Wang L, Desai A, Arce FT, Lal R, Van Eyk JE, Imam SZ, Garcia JG.

Mol Biol Cell. 2010 Nov 15;21(22):4042-56. doi: 10.1091/mbc.E09-10-0876. Epub 2010 Sep 22.

23.

Effect of perioperative opioids on cancer recurrence: a hypothesis.

Singleton PA, Moss J.

Future Oncol. 2010 Aug;6(8):1237-42. doi: 10.2217/fon.10.99.

PMID:
20799870
24.

High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness.

Singleton PA, Mirzapoiazova T, Guo Y, Sammani S, Mambetsariev N, Lennon FE, Moreno-Vinasco L, Garcia JG.

Am J Physiol Lung Cell Mol Physiol. 2010 Nov;299(5):L639-51. doi: 10.1152/ajplung.00405.2009. Epub 2010 Aug 13.

25.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R.

J Biol Chem. 2010 Jun 11;285(24):18575-85. doi: 10.1074/jbc.M109.075085. Epub 2010 Apr 1.

26.

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG.

J Angiogenes Res. 2010 Feb 19;2(1):5. doi: 10.1186/2040-2384-2-5.

27.

Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury.

Mirzapoiazova T, Moitra J, Moreno-Vinasco L, Sammani S, Turner JR, Chiang ET, Evenoski C, Wang T, Singleton PA, Huang Y, Lussier YA, Watterson DM, Dudek SM, Garcia JG.

Am J Respir Cell Mol Biol. 2011 Jan;44(1):40-52. doi: 10.1165/rcmb.2009-0197OC. Epub 2010 Feb 5.

28.

Hyaluronic Acid binding protein 2 is a novel regulator of vascular integrity.

Mambetsariev N, Mirzapoiazova T, Mambetsariev B, Sammani S, Lennon FE, Garcia JG, Singleton PA.

Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):483-90. doi: 10.1161/ATVBAHA.109.200451. Epub 2009 Dec 30.

29.

Dynamin 2 and c-Abl are novel regulators of hyperoxia-mediated NADPH oxidase activation and reactive oxygen species production in caveolin-enriched microdomains of the endothelium.

Singleton PA, Pendyala S, Gorshkova IA, Mambetsariev N, Moitra J, Garcia JG, Natarajan V.

J Biol Chem. 2009 Dec 11;284(50):34964-75. doi: 10.1074/jbc.M109.013771. Epub 2009 Oct 15.

30.

Phosphotyrosine protein dynamics in cell membrane rafts of sphingosine-1-phosphate-stimulated human endothelium: role in barrier enhancement.

Zhao J, Singleton PA, Brown ME, Dudek SM, Garcia JG.

Cell Signal. 2009 Dec;21(12):1945-60. doi: 10.1016/j.cellsig.2009.09.002. Epub 2009 Sep 13.

31.

Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung.

Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, Wang T, Mathew B, Husain A, Moitra J, Sun X, Nunez L, Jacobson JR, Dudek SM, Natarajan V, Garcia JG.

Am J Respir Cell Mol Biol. 2010 Oct;43(4):394-402. doi: 10.1165/rcmb.2009-0223OC. Epub 2009 Sep 11.

32.

Ethnic differences and functional analysis of MET mutations in lung cancer.

Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R.

Clin Cancer Res. 2009 Sep 15;15(18):5714-23. doi: 10.1158/1078-0432.CCR-09-0070. Epub 2009 Sep 1.

33.

Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized phospholipids.

Singleton PA, Chatchavalvanich S, Fu P, Xing J, Birukova AA, Fortune JA, Klibanov AM, Garcia JG, Birukov KG.

Circ Res. 2009 Apr 24;104(8):978-86. doi: 10.1161/CIRCRESAHA.108.193367. Epub 2009 Mar 12.

34.

GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling.

Meyer NJ, Huang Y, Singleton PA, Sammani S, Moitra J, Evenoski CL, Husain AN, Mitra S, Moreno-Vinasco L, Jacobson JR, Lussier YA, Garcia JG.

FASEB J. 2009 May;23(5):1325-37. doi: 10.1096/fj.08-119073. Epub 2009 Jan 5.

35.

Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.

Singleton PA, Garcia JG, Moss J.

Mol Cancer Ther. 2008 Jun;7(6):1669-79. doi: 10.1158/1535-7163.MCT-07-2217.

36.

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG.

Physiol Genomics. 2008 Apr 22;33(2):278-91. doi: 10.1152/physiolgenomics.00169.2007. Epub 2008 Feb 26.

37.

CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.

Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Garcia JG.

J Biol Chem. 2007 Oct 19;282(42):30643-57. Epub 2007 Aug 16.

38.

Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.

Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG.

Cell Signal. 2007 Aug;19(8):1754-64. Epub 2007 Apr 6.

39.

Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.

Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG.

Am J Respir Cell Mol Biol. 2007 Aug;37(2):222-31. Epub 2007 Mar 29.

PMID:
17395891
40.

Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement.

Guo Y, Singleton PA, Rowshan A, Gucek M, Cole RN, Graham DR, Van Eyk JE, Garcia JG.

Mol Cell Proteomics. 2007 Apr;6(4):689-96. Epub 2007 Jan 8.

41.
42.

Endothelial cell barrier enhancement by ATP is mediated by the small GTPase Rac and cortactin.

Jacobson JR, Dudek SM, Singleton PA, Kolosova IA, Verin AD, Garcia JG.

Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L289-95.

43.

Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.

Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J.

Microvasc Res. 2006 Jul-Sep;72(1-2):3-11. Epub 2006 Jul 3.

PMID:
16820176
44.

Hyaluronan-CD44 interaction stimulates keratinocyte differentiation, lamellar body formation/secretion, and permeability barrier homeostasis.

Bourguignon LY, Ramez M, Gilad E, Singleton PA, Man MQ, Crumrine DA, Elias PM, Feingold KR.

J Invest Dermatol. 2006 Jun;126(6):1356-65.

46.
47.

Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.

Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG.

J Biol Chem. 2005 Apr 29;280(17):17286-93. Epub 2005 Feb 14.

48.

Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.

Cao JJ, Singleton PA, Majumdar S, Boudignon B, Burghardt A, Kurimoto P, Wronski TJ, Bourguignon LY, Halloran BP.

J Bone Miner Res. 2005 Jan;20(1):30-40. Epub 2004 Oct 18.

50.

CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion.

Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E.

J Biol Chem. 2004 Jun 25;279(26):26991-7007. Epub 2004 Apr 16.

Supplemental Content

Loading ...
Support Center